viewQ BioMed Inc.

Full interview: Q BioMed positioned 'exceptionally well' to complete milestones with financial restructuring plan

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has launched a financial restructuring plan, where the company’s lead investor Yorkville Advisors Global will convert a minimum of $3.8 million into common stock and preferred stock and may convert an additional $500,000.

Corin says this restructuring positions the company exceptionally well going forward. As part of the agreement, which has yet to close, YA will fund an additional $4 million in new capital over the next 2 weeks.

Quick facts: Q BioMed Inc.

Price: 1.815 USD

Market: OTCQB
Market Cap: $40.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...



Q BioMed activates its marketing campaign for its cancer bone pain drug

Q BioMed Inc (OTCQB:QBIO) Chief Commercialization Officer Kristin Keller tells Proactive the New York-based biotechnology firm has launched a marketing campaign for its non-opioid cancer bone pain drug Strontium89. Keller says the company has created a product website at Strontium89.com to...

1 week, 1 day ago

2 min read